eMedicine Specialties > Pediatrics: General Medicine > Gastroenterology

Malabsorption Syndromes: Differential Diagnoses & Workup

Author: Stefano Guandalini, MD, Director, University of Chicago Celiac Disease Program, Section Chief of Gastroenterology, Hepatology and Nutrition; Professor, Department of Pediatrics, University of Chicago Comer Children's Hospital
Coauthor(s): Richard E Frye, MD, PhD, Assistant Professor, Departments of Pediatrics and Neurology, University of Texas Health Science Center at Houston; M Akram Tamer, MD, Program Director, Professor, Department of Pediatrics, University of Miami
Contributor Information and Disclosures

Updated: Oct 23, 2009

Differential Diagnoses

Congenital Microvillus Atrophy
Giardiasis
Constitutional Growth Delay
Growth Failure
Crohn Disease
Irritable Bowel Syndrome
Cystic Fibrosis
Lactose Intolerance
Diarrhea
Failure to Thrive
Gastroenteritis

Other Problems to Be Considered

Enterokinase deficiency
Hypobetalipoproteinemia
Pancreatic enzyme deficiencies
Pancreatic insufficiency
Intestinal epithelial dysplasia (Tufting enteropathy)

Workup

Laboratory Studies

The following laboratory studies are indicated in malabsorption syndromes:

  • Stool analysis
    • The presence of reducing substances indicates that carbohydrates have not been properly absorbed. One common mistake, especially with the use of superabsorbent diapers, is to test the solid portion of the stool instead of the liquid portion. Furthermore, in stools that are not fresh, bacterial hydrolysis, removal of the reducing substances, and artifactual reduction of pH occur.
    • Acidic stool has a pH level of less than 5.5. This indicates carbohydrate malabsorption, even in the absence of reducing substances.
    • Normally, stool bile acids should not be detected. If bile acid malabsorption is suspected, quantitative conjugated and unconjugated bile acids may be measured in stool, although this test is not routinely available and is not used in routine clinical practice.
    • The level of quantitative stool fat and the amount of fat intake should be measured and monitored for 3 days. Normal fat absorption depends on age (lower in the neonate) and improves throughout the first year of life to the reference range levels of 95% or higher. Moderate fat malabsorption ranges from 60-80%. Fat absorption of less than 50% indicates severe malabsorption.
    • The presence of large serum proteins in the stool, such as a1 -antitrypsin, indicates leakage of serum protein and serves as a screening test for protein-losing enteropathy.
    • Examination of the stool for ova and parasites or testing for the stool antigen may reveal the presence of Giardia species, a known cause of acquired malabsorption syndromes in children who are usually older than 2 years.
    • Testing for other chronic intestinal infections that cause malabsorption, such as Clostridium difficile (assays for toxins A and B) or Cryptosporidium species (modified acid-fast examination of stool), may be performed.
  • Urinalysis
    • Urine examination may reveal an unusually high concentration of the malabsorbed substance because, in many cases, the kidney and the gut use the same transporter.
    • In glucose-galactose malabsorption, the urinary glucose level is typically elevated when the serum glucose level is within reference range because of congenital malfunction of SGLT-1.
    • levels of urinary 4-hydroxyphenylacetic acid have been demonstrated to be elevated in the urine of children with bacterial overgrowth syndrome.
  • Other laboratory studies
    • A CBC count may reveal megaloblastic anemia in patients with folate and vitamin B-12 malabsorption or neutropenia in patients with Shwachman-Diamond syndrome (associated with pancreatic insufficiency). In patients with abetalipoproteinemia, blood smears may reveal acanthocytosis.
    • Total serum protein and albumin levels may be lower than reference range in syndromes in which protein is lost or is not absorbed, particularly in protein-losing enteropathy and pancreatic insufficiency or enterokinase deficiency, respectively.
    • In children with untreated celiac disease, calcium metabolism defects are common and typically return to normal after gluten-free diet. Hence, a detailed, time-consuming, and expensive study of bone metabolism does not appear warranted in children who follow the gluten-free diet.
    • With fat malabsorption or ileal resection, fat-soluble vitamin levels in the serum are lower than reference range.
    • With bile acid malabsorption, levels of the low-density lipoprotein (LDL) cholesterol may be lower than reference range. Another method used to test for bile acid malabsorption is the SeHCAT scanning test.6 Laboratories using this test have shown that bile acid malabsorption is not infrequent in adults with irritable bowel syndrome that presents with chronic diarrhea.7
    • In patients with inflammatory bowel disease, the erythrocyte sedimentation rate, C-reactive protein level, or both are commonly elevated. The value of numerous serological markers of inflammatory bowel diseases (eg, antisaccharomyces cerevisiae antibody [ASCA], perinuclear antineutrophil cytoplasmic autoantibodies [pANCA]) has been repeatedly confirmed in adults, in whom their specificity appears elevated,8 but has not been convincingly demonstrated in children.
    • In patients with liver or biliary disease, the results of liver function tests may be higher than reference range levels. These tests include assays for alanine aminotransferase (ALT), aspartate aminotransferase (AST) in hepatitis, g-glutamyltransferase (GGT), alkaline phosphatase, and bilirubin in cholestatic liver disease.
    • Immunoglobulin G (IgG) and immunoglobulin A (IgA) antigliadin and IgA antiendomysial antibodies, or especially tissue transglutaminase antibodies, are useful in the diagnosis of gluten-sensitive enteropathy.
    • Enterocyte, smooth muscle, thyroid, and islet cell serum antibodies are revealed in patients with autoimmune enteropathy.
    • Recently, a 13C-Sucrose breath test has been proposed as a noninvasive, easy-to-use, integrated marker of the absorptive capacity and integrity of the small intestine.9

Imaging Studies

  • Although upper GI radiography with small bowel follow-through demonstrates a pattern of thickened folds and increased fluid content in the jejunal loops in celiac disease and conditions characterized by protein-losing enteropathies, this test is no longer used because it is unspecific and not sensitive enough, especially when compared with other diagnostic tests.

Procedures

  • Substance tolerance test
    • Attempt to isolate the substance that is causing the malabsorption. Resolution of diarrhea after the suspected substance is removed from the diet and resumption of the diarrhea when the substance is reintroduced are specific signs that the particular substance is not adequately absorbed.
    • If diarrhea does not resolve when the particular substance is removed from the diet, this does not necessarily indicate intolerance to the substance.
    • Malabsorption of certain nutrients can result in secondary intestinal damage and secondary malabsorption, which may no longer be related to the malabsorbed substance. Thus, this technique has low sensitivity until mucosal injury has had a chance to heal.
    • Challenging the patient with the suspected malabsorbed substance once the diarrhea has resolved provides a more sensitive test.
  • Carbohydrate malabsorption tolerance test
    • Carbohydrate malabsorption results in bacterial fermentation. This biochemical process releases hydrogen gas that is absorbed into the blood and excreted by the lungs.
    • Under normal conditions, fermenting bacteria reside in the large intestine. When the bacteria in the large intestine ferment the carbohydrate load, an increase in the level of exhaled hydrogen is detected.
    • The amount of carbohydrate administered is typically 2 g/kg, with a maximum dose of 50 g. When testing for lactose tolerance, using a more physiologic amount (eg, 12.5-25 g) may be preferable.
    • An increase in the exhaled hydrogen concentration following ingestion of an oral carbohydrate load (>20 ppm) indicates carbohydrate malabsorption. Bacterial overgrowth in the small intestine results in an additional early rise in the exhaled hydrogen concentration.
    • Antibiotic administration within the 2 weeks prior to the test may cause false-negative results in this test.
  • D-xylose absorption test
    • Another time-honored test for carbohydrate malabsorption is the D-xylose absorption test. Xylose is a pentose that is passively absorbed by the jejunal mucosa.
    • A standard dose of 5 g or, alternatively, 14.5 g/m2 (maximum dose of 25 g) of D-xylose is orally administered as a 10% solution in water. The test result is positive in the following instances:
      • Children who weigh less than 30 kg - Serum level at 1 hour after ingestion is less than 25 mg/dL.
      • Children who weigh more than 30 kg - The 5-hour urinary excretion is less than 15%.
      • A positive test result suggests malabsorption due to proximal small bowel mucosal lesion (enteropathy).
      • Beware of false-positive results (eg, from delayed gastric emptying, small bowel bacterial overgrowth, accelerated transit time).
  • Mucosal biopsy
    • This test is fundamental in obtaining a definitive diagnosis in many circumstances, such as common celiac disease. Almost all pediatric gastroenterology centers obtain biopsies of the duodenal mucosa during an upper endoscopy.
    • Moderate villous atrophy may be seen in protein-sensitive enteropathies, Giardia infection, or bile acid malabsorption.
    • Histologic examination of the biopsy tissue may reveal the mucosal inclusions seen in abetalipoproteinemia, eosinophilic gastroenteritis, Wolman disease, or congenital microvillous atrophy, for which electron microscopy is needed.
    • Functional assays of the biopsy tissue assess carbohydrate disaccharidase enzymes.

Histologic Findings

  • Biopsy of the small intestine remains the criterion standard for the diagnosis of celiac disease.
  • The classic features include villous atrophy, infiltration of the epithelium by cytotoxic intraepithelial T lymphocytes, and crypt hyperplasia. However, the spectrum can range from a simple intraepithelial lymphocytosis without villous blunting or crypt hyperplasia to total villous atrophy with severe crypt hyperplasia.

More on Malabsorption Syndromes

Overview: Malabsorption Syndromes
Differential Diagnoses & Workup: Malabsorption Syndromes
Treatment & Medication: Malabsorption Syndromes
Follow-up: Malabsorption Syndromes
Multimedia: Malabsorption Syndromes
References

References

  1. Fasano A, Berti I, Gerarduzzi T, et al. Prevalence of celiac disease in at-risk and not-at-risk groups in the United States: a large multicenter study. Arch Intern Med. Feb 10 2003;163(3):286-92. [Medline].

  2. Rubio-Tapia A, Kyle RA, Kaplan EL, et al. Increased prevalence and mortality in undiagnosed celiac disease. Gastroenterology. Jul 2009;137(1):88-93. [Medline].

  3. Abenavoli L, Proietti I, Vonghia L, et al. Intestinal malabsorption and skin diseases. Dig Dis. 2008;26(2):167-74. [Medline].

  4. Scarpellini E, Giorgio V, Gabrielli M, et al. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. J Pediatr. Sep 2009;155(3):416-20. [Medline].

  5. Bruno MJ, Haverkort EB, Tytgat GN, van Leeuwen DJ. Maldigestion associated with exocrine pancreatic insufficiency: implications of gastrointestinal physiology and properties of enzyme preparations for a cause-related and patient-tailored treatment. Am J Gastroenterol. Sep 1995;90(9):1383-93. [Medline].

  6. Ford GA, Preece JD, Davies IH, Wilkinson SP. Use of the SeHCAT test in the investigation of diarrhoea. Postgrad Med J. Apr 1992;68(798):272-6. [Medline].

  7. Wedlake L, A'Hern R, Russell D, Thomas K, Walters JR, Andreyev HJ. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. Oct 2009;30(7):707-17. [Medline].

  8. Mokrowiecka A, Daniel P, Slomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology. Jan-Feb 2009;56(89):162-6. [Medline].

  9. Ritchie BK, Brewster DR, Davidson GP, Tran CD, McNeil Y, Hawkes JS. 13C-sucrose breath test: novel use of a noninvasive biomarker of environmental gut health. Pediatrics. Aug 2009;124(2):620-6. [Medline].

  10. Rizzello CG, De Angelis M, Di Cagno R, et al. Highly efficient gluten degradation by lactobacilli and fungal proteases during food processing: new perspectives for celiac disease. Appl Environ Microbiol. Jul 2007;73(14):4499-507. [Medline].

  11. [Guideline] Hill ID, Dirks MH, Liptak GS, et al. Guideline for the diagnosis and treatment of celiac disease in children: recommendations of the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr. Jan 2005;40(1):1-19. [Medline].

  12. Quigley EM, Quera R. Small intestinal bacterial overgrowth: roles of antibiotics, prebiotics, and probiotics. Gastroenterology. 2006;130:S78-90. [Medline].

  13. Lauritano EC, Gabrielli M, Scarpellini E, et al. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. Eur Rev Med Pharmacol Sci. Mar-Apr 2009;13(2):111-6. [Medline].

  14. Volta U, Granito A, Fiorini E, et al. Usefulness of antibodies to deamidated gliadin peptides in celiac disease diagnosis and follow-up. Dig Dis Sci. Jun 2008;53(6):1582-8. [Medline].

  15. Adachi JA, DuPont HL. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin Infect Dis. Feb 15 2006;42(4):541-7. [Medline].

  16. Cavataio F, Guandalini S. Cow's milk allergy. In: Guandalini S, ed. Essential Pediatric Gastroenterology. McGraw-Hill; 2005:175-92.

  17. Cole CR, Ziegler TR. Small bowel bacterial overgrowth: a negative factor in gut adaptation in pediatric SBS. Curr Gastroenterol Rep. Dec 2007;9(6):456-62. [Medline].

  18. Crenn P, Messing B, Cynober L. Citrulline as a biomarker of intestinal failure due to enterocyte mass reduction. Clin Nutr. Jun 2008;27(3):328-39. [Medline].

  19. Fonnesu C, Giovinale M, Verrecchia E, et al. Gastrointestinal amyloidosis: a case of chronic diarrhoea. Eur Rev Med Pharmacol Sci. Mar 2009;13 Suppl 1:45-50. [Medline].

  20. Goulet O, Ruemmele F. Causes and management of intestinal failure in children. Gastroenterology. 2006;130 (2 Suppl 1):S16-28. [Medline].

  21. Green PH, Jabri B. Celiac disease. Annu Rev Med. 2006;57:207-21. [Medline].

  22. Guandalini S, Dincer AP. Nutritional management in diarrhoeal disease. Baillieres Clin Gastroenterol. 1998;12:697-717. [Medline].

  23. Gupte GL, Beath SV, Kelly DA, et al. Current issues in the management of intestinal failure. Arch Dis Child. 2006;91:259-64. [Medline].

  24. Kneepkens CM, Hoekstra JH. Chronic nonspecific diarrhea of childhood: pathophysiology and management. Pediatr Clin North Am. Apr 1996;43(2):375-90. [Medline].

  25. Longo N, Elsas LJ. Human glucose transporters. Adv Pediatr. 1998;45:293-313. [Medline].

  26. Love MW, Dawson PA. New insights into bile acid transport. Curr Opin Lipidol. Jun 1998;9(3):225-9. [Medline].

  27. Maldonado J, Gil A, Narbona E, Molina JA. Special formulas in infant nutrition: a review. Early Hum Dev. Dec 1998;53 Suppl:S23-32. [Medline].

  28. Montalto M, Curigliano V, Santoro L, et al. Management and treatment of lactose malabsorption. World J Gastroenterol. 2006;12:187-91. [Medline].

  29. Montalto M, Santoro L, D'Onofrio F, Curigliano V, Visca D, Gallo A, et al. Classification of malabsorption syndromes. Dig Dis. 2008;26(2):104-11. [Medline].

  30. Nakamura T, Takeuchi T, Tando Y. Pancreatic dysfunction and treatment options. Pancreas. Apr 1998;16(3):329-36. [Medline].

  31. Robayo-Torres CC, Quezada-Calvillo R, Nichols BL. Disaccharide digestion: clinical and molecular aspects. Clin Gastroenterol Hepatol. 2006;4:276-87. [Medline].

  32. Vignes S, Bellanger J. Primary intestinal lymphangiectasia (Waldmann's disease). Orphanet J Rare Dis. Feb 22 2008;3:5. [Medline].

  33. Weiss B, Skourikhin Y, Modan-Moses D, Broide E, Fradkin A, Bujanover Y. Is adult height of patients with celiac disease influenced by delayed diagnosis?. Am J Gastroenterol. Jul 2008;103(7):1770-4. [Medline].

  34. Zanchi C, Di Leo G, Ronfani L, Martelossi S, Not T, Ventura A. Bone metabolism in celiac disease. J Pediatr. Aug 2008;153(2):262-5. [Medline].

Further Reading

Keywords

malabsorption syndromes, carbohydrate intolerance, chronic diarrhea of infancy, abdominal distention, failure to thrive, intestinal hydrolysis, creatorrhea, monosaccharide intolerance, steatorrhea, protein malabsorption, cystic fibrosis, Shwachman-Diamond syndrome, congenital lactase deficiency, amylase deficiency, adult-type hypolactasia, lactose intolerance, enteritis, mucosal atrophy, enterokinase deficiency, milk protein allergy enteropathy, steatorrhea, soy milk protein allergy, malnutrition, Giardia infections, abdominal pain, inflammatory bowel disease, borborygmi, protein sensitivity, pancreatic insufficiency, pancreatitis, pancreatic cancer, pancreatic resection, Johnson-Blizzard syndrome, Pearson syndrome, abetalipoproteinemia, protein-losing enteropathy, congenital enterokinase deficiency, Crohn disease

Contributor Information and Disclosures

Author

Stefano Guandalini, MD, Director, University of Chicago Celiac Disease Program, Section Chief of Gastroenterology, Hepatology and Nutrition; Professor, Department of Pediatrics, University of Chicago Comer Children's Hospital
Stefano Guandalini, MD is a member of the following medical societies: American Gastroenterological Association, European Society for Paediatric Gastroenterology, Hepatology & Nutrition, and North American Society for Pediatric Gastroenterology and Nutrition
Disclosure: Nothing to disclose.

Coauthor(s)

Richard E Frye, MD, PhD, Assistant Professor, Departments of Pediatrics and Neurology, University of Texas Health Science Center at Houston
Richard E Frye, MD, PhD is a member of the following medical societies: American Academy of Neurology, American Academy of Pediatrics, Child Neurology Society, and International Neuropsychological Society
Disclosure: Nothing to disclose.

M Akram Tamer, MD, Program Director, Professor, Department of Pediatrics, University of Miami
M Akram Tamer, MD is a member of the following medical societies: American Medical Association and Florida Medical Association
Disclosure: Nothing to disclose.

Medical Editor

Alan D Schmetzer, MD, Professor and Vice-Chair for Education, Director of Residency Training, Department of Psychiatry, Indiana University School of Medicine
Alan D Schmetzer, MD is a member of the following medical societies: American Association for the Study of Liver Diseases, American Gastroenterological Association, American Society of Transplant Surgeons, and North American Society for Pediatric Gastroenterology and Nutrition
Disclosure: Nothing to disclose.

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

B UK Li, MD, Professor of Pediatrics, Division of Gastroenterology, Hepatology and Nutrition, Director, Pediatric Fellowships and Gastroenterology Fellowship, Medical Director, Functional Gastrointestinal Disorders and Cyclic Vomiting Program, Medical College of Wisconsin; Attending Gastroenterologist, Children's Hospital of Wisconsin
B UK Li, MD is a member of the following medical societies: Alpha Omega Alpha, American Gastroenterological Association, and North American Society for Pediatric Gastroenterology and Nutrition
Disclosure: Nothing to disclose.

CME Editor

Steven M Schwarz, MD, FAAP, FACN, AGAF, Professor of Pediatrics, Children's Hospital at Downstate, SUNY-Downstate Medical Center
Steven M Schwarz, MD, FAAP, FACN, AGAF is a member of the following medical societies: American Academy of Pediatrics, American College of Nutrition, American College of Physician Executives, American Gastroenterological Association, American Pediatric Society, Gastroenterology Research Group, New York Academy of Medicine, North American Society for Pediatric Gastroenterology and Nutrition, and Society for Pediatric Research
Disclosure: TAP Pharmaceuticals Honoraria Speaking and teaching; Curemark, LLC Consulting fee Board membership; Centocor, Inc. Grant/research funds Independent contractor

Chief Editor

Carmen Cuffari, MD, Associate Professor, Department of Pediatrics, Division of Gastroenterology/Nutrition, Johns Hopkins University School of Medicine
Carmen Cuffari, MD is a member of the following medical societies: American College of Gastroenterology, American Gastroenterological Association, North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, and Royal College of Physicians and Surgeons of Canada
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.